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ABSTRACT  
A  simple,  efficient  and  reproducible  Reverse  Phase-High  Performance  Liquid  Chromatography  (RP-HPLC)  method  for  simultaneous  determination  of 
Clindamycin phosphate and Clotrimazole in combined soft gelatin pessaries pharmaceutical formulation has been developed. The separation was carried out 
on Hypersil BDS C8 (250 × 4.6 mn; 5 µm) column using buffer, 13.6 g Potassium dihydrogen ortho phosphate in 1000 ml of water (adjusted to pH 2.5 ortho 
phosphoric acid): acetonitrile: l in the ratio of 70:30 v/v as eluent. The flow rate was 1.0 ml / min and effluent was detected at 210 nm. The retention times of 
Clindamycin phosphate and Clotrimazole were 4.47 minutes, 22.06 minutes and 12.03 minutes respectively. The percentage recovery was within the range 
between 102.2 % and 103.23 % for Clindamycin phosphate, 98.96 % and 100.54 % for Clotrimazole. The linear ranges were found to be 200 mg / ml (r
2 = 
0.9998) for Clindamycin phosphate, 400 mg / ml (r
2 = 0.9895) for Clotrimazole. The percentage relative standard deviation for accuracy and precision was 
found to be less than 2 %. The linearity was found to be in the range of 80-120 mg / ml and correlation coefficient of were found to be 0.9998, 0.9979, for 
Clindamycin  Phosphate,  Clotrimazole  respectively.  The  proposed  method  is  accurate  with  102  %  recovery  and  precise  (%  RSD  of  Reproducibility 
repeatability,  intra-day  and  inter-day  variations  were  0.19,  0.24,  0.44,  0.78,  0.12-0.15,  0.13-0.37,  0.14,  0.22).  The  method  was  successfully  applied to 
pharmaceutical formulation because no chromatographic interferences from peccaries excipients were found. 
Keywords: Clindamycin, Clotrimazole RP-HPLC, Validation, Acetonitrile, Methanol. 
 
INTRODUCTION 
Clindamycin  is  a  lincosamide  antibiotic  that  has  been 
approved by the US Food and Drug Administration (FDA) 
for  the  treatment  of  anaerobic,  streptococcal  and 
staphylococcal infections. There has been increased interest 
in  the  use  of  clindamycin  because  it  achieves  high 
intracellular levels  in  phagocytic  cells,  high  levels  in  bone 
and  appears  to  have  an  antitoxin  effect  against  toxin 
elaborating strains of streptococci and staphylococci. 
 
 
 
Figure 1: Structure of Clindamycin phosphate 
 
 
     
Figure 2: Structure of Triclomazole 
 
Clindamycin (C18H34ClN2O8PS) is  a  methyl 7-chloro-6,7,8-
trideoxy-6-(1-methyl-trans-4-propyl-L-2-
pyrrolidinecarboxamido)-1-thio-L-threo-D-galacto-
octopyranoside2-(dihydrogenphosphate).  Molecular  weight 
504.9 g / mol. Clindamycin shows broad spectrum activity. It 
elicits more activity against Gram positive organisms but is 
also  being  effective  against  Gram  negative  bacteria, 
anaerobes and protozoa. When used orally, clindamycin is 
reserved for severe bacterial infections such as female genital 
infection  and  lower  respiratory  infections  caused  by 
anaerobic  organisms,  staphylococci,  streptococci, 
pneumococci.  Topically,  it  is  used  for  acne  vulgaris  and 
bacterial  vaginosis
1.  Clotrimazole  (C22H17ClN2)  is  a  1-[(2-
chlorophenyl)  (diphenyl)methyl]-1H-imidazole.  Molecular 
weight 344.8 g / mol. Clotrimazole is imidazole deriative that 
is  a  broad  spectrum  fungicidal  drug.  Clotrimazole  is  most 
valuable  for  the  treatment  of  superficial  fungal  infection 
caused  by  dermatophytes,  yeasts  and  yeast  like  fungi. 
Clotrimazole is a topically used azole. The requirement for 
intravenous  administration  and  the  toxicity  of  the  older 
antifungal agents created a need for antifungal agents with a 
better therapeutic profile. The relatively non-toxic oral azole 
medications  represent  the  first  major  advance  in  this 
direction.
2,3 Literature survey reveals that few HPLC methods 
have  been  reported  for  the  estimation  of  clindamycin 
phosphate combination with other drugs. Till now, there is no 
simple  RP-HPLC  method  has  been  reported  using  simple 
solvents.  The  main  objective  of  the  present  study  is  to 
develop  simple,  sensitive,  accurate  and  precise  RP-HPLC 
method  for  estimation  of  clindamycin  phosphate  in 
pharmaceutical dosage forms. The validation has been carried 
out as per ICH guidelines. 
 
MATERIALS AND METHODS 
Instrumentation and Chromatographic Conditions 
The  chromatographic  separation  was  carried  out  on  HPLC 
system  (Shimadzu  S.No.  2124404405  Kyoto,  Japan)  with 
UV- Visible dual absorbance detector (PDA), Hypersil BDS 
C8  column  (250  x  4.6  mm;  5  µm).  The  mobile  phase 
consisting  of  13.6  ml  of  Potassium  dihydrogen  ortho 
phosphate  in  1000  ml  water  (pH  2.5  adjusted  with 
orthophosphoric acid), acetonitrile and methanol were filtered 
through  0.45  µ  membrane  filter  before  use,  degassed  and R. Rajameena et al. Int. Res. J. Pharm. 2013, 4 (7) 
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were pumped from the solvent reservoir in the ratio of 70:30 
v/v was then pumped into the column at a flow rate of 1.0 ml 
/ min. The detection was monitored at 210 nm. The volume 
of injection loop was 20 µl prior to the injection of the drug 
solution; the column was equilibrated for at least 30 minutes 
with the mobile phase following through the system.  
 
Reagents and Materials 
The  reference  sample  of  Clindamycin  phosphate  and 
Clotrimazole  were  supplied  by  Gujarat  Organic  Ltd, 
Lucknow,  India.  The  formulation  was  procured  from  the 
local market. HPLC grade methanol, acetonitrile, OPA was 
purchased from Alchymars Icm sm Private Limited, Chennai, 
India. 
 
Selection of Mobile Phase 
Based on sample solubility, stability and suitability various 
mobile  phase  compositions  were  tried  to  get  a  good 
resolution and sharp peak. The standard solution was run in 
different mobile phases. From the mobile phase consisting of 
13.6 ml of Potassium dihydrogen ortho phosphate in 1000 ml 
water  (pH  2.5  adjusted  with  orthophosphoric  acid), 
acetonitrile  and  methanol  were  filtered  through  0.45  µ 
membrane filter before use, degassed and were pumped from 
the  solvent  reservoir  in  the  ratio  of  70:30  v/v  was  then 
pumped into the column at a flow rate of 1.0 ml / min with 
detection at 210 nm. 
 
Preparation of Standard Stock Solution 
Clindamycin Phosphate Working Standard Solution  
24  mg  of  Clindamycin  Phosphate  working  standard  was 
weighed and transferred carefully in 50 ml volumetric flask. 
About  20  ml  of  mobile  phase  was  added,  sonicated  to 
dissolve the drug completely and the volume was made up 
with mobile phase. 2 ml of above solution was diluted to 50 
ml with mobile phase (20 μg / ml).  
 
Clotrimazole Working Standard Solution  
40 mg  of Clotrimazole working standard was weighed and 
transferred carefully in 50 ml volumetric flask. About 20 ml 
of  mobile phase was  added, sonicated to dissolve the drug 
completely and the volume was made up with mobile phase 
(500 μg / ml). 
 
Preparation of Calibration Curve 
Aliquots  of  0.5,  1,  1.5,  2,  2.5,  3,  3.5  ml  standard  stock 
solution (100 μg / ml) was transferred to 10 ml of volumetric 
flasks  and  made  up  to  the  mark  with  mobile  phase  to  get 
concentration of 5,10,15,20,25,30,35 μg / ml. An aliquot (20 
μl)  of  each  solution  was  injected  under  the  operating 
chromatographic  conditions  and  responses  were  recorded. 
Calibration curve was constructed by plotting the peak areas 
versus  the  concentration  and  the  regression  equation  was 
calculated.  The  standard  solution  was  prepared  by 
transferring 1.5 ml of 100 μg / ml to the 10 ml of volumetric 
flask and made up to the mark with mobile phase to get 15 μg 
/ ml. 
 
Sample Preparation 
1500 mg of the sample pessaries was weighed and transferred 
carefully  in  a  clean  and  dry  100  ml  volumetric  flask  and 
make up the volume to 50 ml of mobile phase. 5 ml of above 
solution was diluted to 25 ml with mobile phase.  
 
Amount of Clindamycin Phosphate / Clotrimazole / in each of the Pessariss 
Sample are         SW      100       25       425     Purity 
=    --------------- x   ----- x ----- x ---  x ------ x ------ x  Av. wt 
Standard area     100       TW       5        505      100 
Where, 
SW  = Standard weight taken in mg. TW = Test weight taken in mg. Av.wt. = Average net content in mg. Purity = Purity of Clindamycin Phosphate 
 
Method Validation 
The  optimized  Chromatographic  method
4,5  was  completely 
validated  according  to  the  procedures  described  in  ICH 
guidelines Q2 (R1) for the validation of analytical methods 
(ICH,2005)
6. 
 
System Suitability Test 
System suitability parameters are evaluated by following ICH 
guidelines injecting five replicates of 20 µg / ml, 500 µg / ml 
and  300  µg  /  ml  concentrations  of  standards  Clindamycin 
Phosphate,  Clotrimazole,  respectively.  Resolution  factor, 
theoretical  plate  and  tailing  factors  were  evaluated  by 
following ICH guidelines.  
 
Specificity 
Specificity is the degree to which the procedure applies to a 
single analyte and is checked in each analysis by comparing 
the blank chromatogram with the chromatogram obtained for 
the drug spiked with internal standard (placebo) to trace out 
the  interfering  peaks.  The  specificity  of  the  method  was 
investigated  by  the  analysis  of  the  two  blank  preparation 
spiked  with  two  different  concentration  of  standards, 
Clindamycin Phosphate, Clotrimazole, sample, pessaries and 
internal  standard  (placebo)  was  also  added.  The  mean 
standard deviation and RSD of specificity were calculated. 
 
Linearity 
The linearity of the peak area response was determined by 
making six measurements a five concentration points in the 
range  of  80  %  mg  /  ml  to  120  %  mg  /  ml  of  operating 
concentrations  of  standards,  Clindamycin  Phosphate, 
Clotrimazole.  Standard  area  was  plotted  against  the 
concentration.  The  linear  regression  coefficient,  correlation 
coefficient, standard deviation and mean were calculated.  
 
Precision 
The precision of an analytical method is the closeness of a 
series  of  individual  measurements  of  an  analyte  when  the 
analytical  procedure  is  applied  repeatability  to  multiple 
aliquots  of  a  single  homogeneous  volume  of  biological 
matrix.  Precision  is  calculated  as  coefficient  of  variation, 
relative  standard  deviation.  The  measure  RSD  can  be 
subdivided  into  two  categories:  repeatability  (intra-  day 
precision) and reproducibility. 
 
Reproducibility 
Reproducibility  of  the  method  assessed  by  analyzing  six 
times  of  100  mg  /  ml,  200  mg  /  ml  concentrations  of 
standards,  Clindamycin  phosphate  and  Clotrimazole 
respectively.  The  mean,  standard  deviation  and  RSD  of 
reproducibility were calculated. 
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Repeatability 
Repeatability of the peak area response was determined by 
making  six  measurements  at  six  different  concentration 
points  of  sample  pessaries  and  it  is  compared  with  the 
standard  drugs  Clindamycin  phosphate,  Clotrimazole.  The 
mean,  standard  deviation  and  RSD,  of  repeatability  were 
calculated.  
 
Accuracy 
The  accuracy  was  assessed  by  using  a  minimum  of  three 
different  concentrations  of  standards,  Clindamycin 
phosphate, Clotrimazole, 80 % mg / ml to 120 % mg / ml of 
placebo  spiked  into  the  standard  solution  of  Clindamycin 
phosphate, Clotrimazole, The mean, standard deviation and 
RSD of accuracy were calculated.  
 
Robustness 
Robustness was determined by injecting triplicate injection of 
standards and three sample solutions in single and at different 
concentration with respect to control condition. Robustness 
of the method was checked by varying the mobile phase ratio. 
The  sample  and  standard  solutions  were  injected  in  each 
condition,  mean,  standard  deviation  and  relative  standard 
deviation, of robustness were calculated. 
 
 
 
 
Ruggedness 
Robustness  is  defined  as  the  degree  of  reproducibility  of 
results  obtained  under  a  variety  of  conditions,  such  as 
different  laboratories,  analysts,  instruments,  environmental 
conditions, operators and materials. Ruggedness is a measure 
of  reproducibility  of  test  results  under  normal,  expected 
operational conditions from laboratory to laboratory and from 
analyst to analyst. Ruggedness of the method was checked by 
the analysis of sample aliquots from homogeneous lots by a 
different chemist on a different instrument on a different day. 
 
RESULTS AND DISCUSSIONS 
A  simple,  efficient  and  reproducible  Reverse  Phase-High 
Performance Liquid Chromatography (RP-HPLC) method for 
simultaneous  determination  of  Clindamycin  phosphate  and 
Clotrimazole  in  combined  soft  gelatin  pessaries 
pharmaceutical  formulation  has  been  developed.  The 
Separation was carried out on Hypersil BDS C8 (250 × 4.6 
mn; 5 µm) column using buffer, 13.6 g Potassium dihydrogen 
ortho  phosphate  in  1000  ml  of  water  (adjusted  to  pH  2.5 
ortho phosphoric acid): acetonitrile: l in the ratio of 70:30 v/v 
as eluent. The flow rate was 1.0 ml / min and effluent was 
detected  at  210  nm.  The  retention  times  of  Clindamycin 
phosphate  and  Clotrimazole  were  4.47  minutes,  22.06 
minutes  and  12.03  minutes  respectively.  The  percentage 
recovery was within the range between 102.2 % and 103.23 
%  for  Clindamycin  phosphate,  98.96  %  and  100.54  %  for 
Clotrimazole. 
 
Table 1: System Suitability for Clindamycin Phosphate and Clotrimazole 
 
S. No.  Standard  Concentration (µg/ml)  Area 
  Clindamycin  Clotrimazole  Clindamycin  Clotrimazole  Clindamycin  Clotrimazole 
1.  Standard -1  Standard -1  100  200  910864  28741520 
2.  Standard -2  Standard -2  100  200  913962  28821992 
3.  Standard -3  Standard -3  100  200  912694  28910527 
4.  Standard -4  Standard -4  100  200  921951  28911919 
5.  Standard -5  Standard -5  100  200  912633  28885018 
6.  Standard -6  Standard -6  100  200  912273  28790175 
Mean  929917  28843525 
Standard deviation  1807.768  70147.83 
RSD in %  0.194401  0.243201 
 
System suitability parameters  Clindamycin Phosphate  Clotrimazole 
Retention time  4.47 minutes  22.06 minutes 
Peak area response  929917  28843525 
 
Table 2: Specificity for Clindamycin Phosphate and Clotrimazole 
 
S. No.  Name  No. of Injections  Area 
Clindamycin Phosphate  Clotrimazole 
1.  Blank  1  Nil  Nil 
2.  Placebo  1  Nil  Nil 
3.  Standard  1  910864  28741520 
4.  Sample  1  937463  28257715 
 
 
 
Figure 3: Typical chromatogram of Placebo 
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Figure 4: Typical chromatogram of Clindamycin Phosphate and Clotrimazole 
 
The Linearity of this method was determined at five levels 
from  80  %  –  120  %  of  operating  concentrations  for 
Clindamycin Phosphate, Clotrimazole and it was shown in 
Table  3.  The  plot  of  peak  area  of  each  sample  against 
respective  concentration  of  Clindamycin  Phosphate, 
Clotrimazole were found to be linear (Figure 5 and 6) in the 
range of 80 % – 120 % of operating concentrations. Beer’s 
law was found to be obeyed over this concentration range. 
The  linearity  was  evaluated  by  linear  regression  analysis 
using least square method. The regression equations were 
found to be Y= 4488.3x – 3906.8, Y= 68651x – 245607, for 
Clindamycin  Phosphate,  Clotrimazole,  respectively  and 
correlation coefficient of the standard curves were found to 
be  0.9998,  0.9979,  for  Clindamycin  Phosphate, 
Clotrimazole,  respectively.  It  observed  that  correlation 
coefficient and regression analysis are within the limits.   
  
Table 3: Linearity of response for Clindamycin Phosphate and Clotrimazole 
 
S. No.  Linearity 
Level 
Volume of stock 
solution (ml) 
Volume made up to 
(ml) 
Concentration (µg/ml)  Area 
Clindamycin  Clotrimazole  Clindamycin  Clotrimazole 
1.  Linearity -1  4.0  10  160  320  721835  21708770 
2.  Linearity -2  4.5  10  180  360  811658  24457714 
3.  Linearity -3  5.0  10  200*  400*  900505  27417966 
4.  Linearity -4  5.5  10  110  440  994711  29642489 
5.  Linearity -5  6.0  10  120  480  1079140  32846533 
*Operating concentration 
 
 
 
Figure 5: Linearity of response for Clindamycin Phosphate Figure 
 
 
 
Figure 6: Linearity of response for Clotrimazole 
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Accuracy of the method was found out by recovery study by 
standard addition method. The known amounts of standards, 
Clindamycin  Phosphate,  Clotrimazole,  were  added  to  pre-
analyzed samples at a level from 80 % mg / ml up to 120 % 
mg / ml. The results of recovery studies were shown in Table 
4. It was observed that the mean percentage recoveries were 
found  to  be  for  Clindamycin  Phosphate,  Clotrimazole, 
respectively. 
 
Table 4: Accuracy for Clindamycin Phosphate and Clotrimazole 
 
S. No.  Area  Amount recovered (mg)  Recovery (%) 
  Clindamycin  Clotrimazole  Clindamycin  Clotrimazole  Clindamycin  Clotrimazole 
1.  753295  22457823  23.96  321.76  102.67  100.54 
2.  751422  22653066  23.99  324.56  102.41  101.41 
3.  750463  22352550  24.00  320.25  102.28  100.07 
4.  942503  27967598  29.61  400.70  102.76  100.16 
5.  946817  28321138  29.59  405.77  103.23  101.43 
6.  946720  28378339  29.55  406.59  103.22  101.64 
7.  1129138  33157804  35.32  475.07  102.59  98.96 
8.  1124825  33662566  35.47  482.30  102.20  100.47 
9.  1125348  33639096  35.39  481.96  102.25  100.40 
Mean  102.71  100.51 
Standard deviation  0.008  0.003 
 
The  precision  of  an  analytical  procedure  expresses  the 
closeness of agreement between a series of measurements 
obtained  from  multiple  sampling  of  the  homogenous 
sample  under  the  prescribed  conditions.  Reproducibility 
data  for  Clindamycin  Phosphate,  Clotrimazole,  were 
shown in Table 5. This indicated that method was highly 
precise. 
 
Table 5: Precision – Reproducibility for Clindamycin Phosphate and Clotrimazole 
 
S. No.  Sample name  Concentration (µg/ml)  Area 
Clindamycin  Clotrimazole  Clindamycin  Clotrimazole 
1.  Standard -1  100  200  910864  28741520 
2.  Standard -2  100  200  913962  28821992 
3.  Standard -3  100  200  912694  28910527 
4.  Standard -4  100  200  921951  28911919 
5.  Standard -5  100  200  912633  28885018 
6.  Standard -6  100  200  912273  28790175 
Mean    929917  28843525 
Standard deviation    1807.768  70147.83 
RSD in %    0.194401  0.243201 
 
Repeatability  is  the  precision  of  a  method  under  the  same 
operating conditions over a short period of time. One aspect 
of  this  is  instrumental  precision.  A  second  aspect  is 
sometimes termed intra-assay precision and involves multiple 
measurements of the same sample by the same analyst under 
the  same  conditions.  Repeatability  data  for  Clindamycin 
Phosphate,  Clotrimazole  were  shown  in  Table  6.  This 
indicated that method was highly precise. 
 
Table 6: Precision - Repeatability for Clindamycin Phosphate and Clotrimazole 
 
S. No.  Sample Name  Wt. taken (g)  No. of reading  Area  Amount (mg / 5 ml) 
Clindamycin  Clotrimazole    Clindamycin  Clotrimazole  Clindamycin  Clotrimazole 
1.  Sample -1  1.5038  1.5038  1  937463  28257715  99.92  197.83 
2.  Sample -2  1.5031  1.5031  1  941506  28941382  100.39  202.71 
3.  Sample -3  1.5045  1.5045  1  938216  28654640  99.95  200.51 
4.  Sample -4  1.5022  1.5022  1  929704  28673427  99.20  200.95 
5.  Sample -5  1.5011  1.5011  1  932806  28646903  99.60  200.91 
6.  Sample -6  1.5056  1.5011  1  941953  28684170  100.28  200.57 
Mean  99.89  200.58 
Standard deviation  0.4414409  1.572151 
RSD in %  0.4419318  0.783805 
 
Robustness  data  Clindamycin  Phosphate,  Clotrimazole  by 
changing  the  ratio  of  solvents  in  the  mobile  phase.  It  was 
shown in Table 7 and 8. It was observed that there were no 
marked changes in the chromatograms, which demonstrated 
that the proposed method was robust. 
 
Table 7: Robustness - Change in the ratio of solvents in the mobile phase (± 2) for Clindamycin Phosphate 
 
S. No.  Sample Name  Wt. taken (g)  Area 
(Buffer: Acetonitrile) 
Amount (mg / 5 ml) 
(Buffer: Acetonitrile) 
70:30  72:28  70:30  72:28 
1.  Sample -1  1.4926  914377  913563  100.14  100.05 
2.  Sample -2  1.4942  917031  914115  100.32  100.27 
Mean  100.23  100.16 
Standard deviation  0.129  0.155 
RSD in %  0.12  0.15 R. Rajameena et al. Int. Res. J. Pharm. 2013, 4 (7) 
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Table 8: Robustness - Change in the ratio of solvents in the mobile phase (± 2) for Clotrimazole 
 
S. 
No. 
Sample 
Name 
Wt. taken 
(g) 
Area 
(Buffer: Acetonitrile) 
Amount (mg / 5 ml) 
(Buffer: Acetonitrile) 
70:30  72:28  70:30  72:28 
1.  Sample -1  12.4014  26649114  27798505  198.47  200.25 
2.  Sample -2  12.7135  26628583  27606287  198.11  199.18 
Mean  198.29  199.72 
Standard deviation  0.25  0.75 
RSD in %  0.13  0.37 
 
Six  sample  preparations  were  analyzed  as  per  the 
methodology by a different analyst on a different instrument 
on  a  different  day.  The  robustness  data  Clindamycin 
Phosphate,  Clotrimazole,  were  shown  in  Table  9.  It  was 
observed  that  there  were  no  marked  changes  in  the 
chromatograms,  which  demonstrated  that  the  proposed 
method was robust. 
 
Table 9: Ruggedness data for Clindamycin Phosphate - Change of analyst 
 
S. No.  Sample Name  Wt. taken (g)  Area  Amount (mg / 5 ml) 
Clindamycin  Clotrimazole  Clindamycin  Clotrimazole  Clindamycin  Clotrimazole 
1.  Sample -1  1.5022  1.5022  946058  28256527  99.58  200.97 
2.  Sample -2  1.5036  1.5036  945896  28338484  99.47  201.37 
3.  Sample -3  1.5015  1.5015  945461  28341292  99.57  201.67 
4.  Sample -4  1.5038  1.5038  945881  28257280  99.46  200.77 
5.  Sample -5  1.5065  1.5065  945909  28341308  99.28  201.00 
6.  Sample -6  1.5065  1.5065  945409  28256972  99.23  200.40 
Mean  99.43  201.03 
Standard deviation  0.14  0.44 
RSD in %  0.14  0.22 
  
CONCLUSION 
The  proposed  study  describes  new  and  simple  RP-HPLC 
method  for  the  simultaneous  estimation  of  Clindamycin 
phosphate  and  Clotrimazole  in  combined  soft  gelatin 
pessaries  dosage  form.  The  method  was  validated  as  per 
ICH guidelines and found to be simple, sensitive, accurate 
and  precise.  Therefore  the  proposed  method  can  be 
successfully used for the routine analysis of simultaneous 
estimation of Clindamycin phosphate and Clotrimazole in 
combined  soft  gelatin  pessaries  dosage  form  without 
interference. 
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